True North Therapeutics Appoints James Gilbert, M.D., As Chief Medical Officer - 6/17

True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, today announced the appointment of James Gilbert, M.D., as the Company's first Chief Medical Officer (CMO). As CMO, Dr. Gilbert will oversee all clinical development and regulatory activities for the company, as True North advances its lead product candidate, TNT009, into human clinical trials for autoantibody-driven rare diseases that are mediated by the Complement system.

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.